Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 358,500 shares, a drop of 9.1% from the July 15th total of 394,500 shares. Based on an average daily volume of 113,700 shares, the days-to-cover ratio is currently 3.2 days.

Capricor Therapeutics Trading Up 3.1 %

NASDAQ CAPR opened at $5.26 on Thursday. Capricor Therapeutics has a 52 week low of $2.56 and a 52 week high of $5.85. The company has a 50 day moving average price of $4.38 and a 200 day moving average price of $4.03.

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) last issued its quarterly earnings results on Wednesday, August 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04). During the same period last year, the business earned ($0.21) earnings per share. As a group, equities analysts forecast that Capricor Therapeutics will post -1.17 EPS for the current year.

Wall Street Analyst Weigh In

Insiders Place Their Bets

In other Capricor Therapeutics news, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the completion of the sale, the director now directly owns 12,747 shares in the company, valued at approximately $48,056.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director David B. Musket sold 17,775 shares of the business's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $4.44, for a total value of $78,921.00. Following the completion of the transaction, the director now owns 40,962 shares of the company's stock, valued at $181,871.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the sale, the director now owns 12,747 shares of the company's stock, valued at approximately $48,056.19. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Selective Wealth Management Inc. purchased a new stake in shares of Capricor Therapeutics during the first quarter worth about $732,000. Vanguard Group Inc. increased its stake in Capricor Therapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock valued at $3,502,000 after purchasing an additional 54,260 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Capricor Therapeutics by 54.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock valued at $510,000 after purchasing an additional 52,611 shares in the last quarter. Bailard Inc. purchased a new position in shares of Capricor Therapeutics in the second quarter worth $104,000. Finally, UBS Group AG grew its holdings in shares of Capricor Therapeutics by 326.0% during the second quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after buying an additional 22,462 shares during the last quarter. 9.49% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

(Get Rating)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

See Also

• Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
• Which Semiconductor Stocks Are Ready For Big Price Moves?
• Miners Advance On Earnings Despite Broader Economic Challenges
• Agilent Technologies Proves Its Worth VS Illumina
• Lowe's Stands Out Amid Q2 Retail Reports
• Target's Results Cap Upside Potential For Retail Stocks

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.